Bevacizumab for Recurrent Malignant Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

March 31, 2011

Study Completion Date

February 28, 2014

Conditions
Recurrent High-Grade GliomasMalignant Gliomas
Interventions
DRUG

Bevacizumab

10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00271609 - Bevacizumab for Recurrent Malignant Glioma | Biotech Hunter | Biotech Hunter